"Adalimumab-induced interstitial lung disease is a form of anti-TNF-induced diffuse interstitial lung disease from the broader category of drug-induced lung disease. The disease occurs as a response to the disease-modifying anti-rheumatic drug (DMARD), adalimumab."
"The exact mechanism of pulmonary toxicity is unclear with one thought being the inhibition of inflammatory cells by anti-TNF drugs leading to unopposed activity of inflammatory cells resulting in characteristic changes of interstitial pneumonitis."